Cepheid

Cepheid is a biotechnology company founded in 1996 with a focus on improving healthcare through innovative molecular diagnostics. The company's GeneXpert® systems and Xpert® tests streamline complex and time-consuming manual procedures, offering a more efficient way for institutions to conduct PCR testing. Cepheid's test portfolio covers a wide range of medical areas, including respiratory infections, blood virology, women's health, TB, oncology, and more, delivering actionable results in various healthcare settings. As part of Danaher, Cepheid benefits from the vast resources and expertise of the parent company, enhancing its impact in the industry. Recently, Cepheid received a grant investment on 22 October 2021. Although the specific investors are not disclosed, this investment signifies confidence in the company's innovative approach to molecular diagnostics. With its dedication to advancing healthcare and its association with Danaher, Cepheid is poised to continue making significant contributions to the biotechnology and healthcare sectors.